ImPact Biotech

Company Overview

Snapshot

Founded in January 1996, ImPact Biotech operates with 11–50 employees and has raised $2.7M across one funding round. The company recently announced 50% enrollment in its Phase 3 ENLIGHTED Clinical Trial for Padeliporfin VTP in low-grade upper tract urothelial cancer.

Business overview

ImPact Biotech is a Health Tech & Life Sciences company focused on developing and commercializing Padeliporfin Vascular Targeted Photodynamic (VTP) therapy. This oncology technology platform utilizes intravenous delivery of an inactive drug, Padeliporfin, activated by non-thermal laser light directly within the tumor micro-environment. The therapy aims for selective tumor ablation by occluding tumor blood supply and inducing immunogenic cell death with minimal impact on healthy tissues. The company holds exclusive rights from the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center for VTP drugs and related technologies.

Strategic signal

In September 2024, ImPact Biotech announced 50% enrollment in its Phase 3 ENLIGHTED Clinical Trial for Padeliporfin VTP in low-grade upper tract urothelial cancer. This milestone indicates significant progress in the clinical development of their novel oncology platform, signaling strong operational momentum and potential for future market entry in the targeted cancer therapy space.

Company Intelligence Q&A

What is ImPact Biotech's core technology?

ImPact Biotech develops Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a novel oncology platform that uses an intravenously delivered inactive drug, Padeliporfin, activated by non-thermal laser light to selectively ablate tumors.

When did ImPact Biotech receive a grant from the European Innovation Council?

In July 2024, ImPact Biotech secured a grant from the European Innovation Council.

What was a significant clinical trial update for ImPact Biotech in September 2024?

In September 2024, ImPact Biotech announced 50% enrollment in its Phase 3 ENLIGHTED Clinical Trial of Padeliporfin VTP for low-grade upper tract urothelial cancer.

When did ImPact Biotech present preliminary Phase 3 results for its ENLIGHTED study?

In May 2024, ImPact Biotech presented preliminary Phase 3 results from its ENLIGHTED study of Padeliporfin VTP in low-grade upper tract urothelial cancer.

When did ImPact Biotech receive FDA clearance for its IND Application for Padeliporfin VTP in pancreatic cancer?

In December 2023, ImPact Biotech received FDA clearance of its Investigational New Drug (IND) Application for Padeliporfin VTP in pancreatic cancer.